Systemic Scleroderma clinical trials
44 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
- RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Platform Clinical Study for Conquering Scleroderma
- A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
- TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis
- Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
- A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Systemic Sclerosis DIet for GastrointESTinal Symptoms
- Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
- A Study of AZD0120 in Autoimmune Diseases
- A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
- Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
- A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Intralesional Injection of STS in Treatment of Calcinosis
- Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
- AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
- A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis
- A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Open Label Treprostinil Raynaud's Study
- The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
- Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images
- US Zamto-cel Autoimmune Diseases
- A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
- A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
- Rheumatology Patient Registry and Biorepository
- New Orleans Pulmonary Hypertension Biobank
- Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
- TENS in Scleroderma
- A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
- Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial
- BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
- Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
- A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
- Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Systemic Scleroderma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.